Loading
A phase 3 trial testing Acasunlimab in non-small-cell lung cancer, active and no longer recruiting.
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) is a phase 3 interventional study registered as NCT06635824, led by Genmab, and active but no longer recruiting on the registry. Official title: A Prospective, Open-Label, Randomised, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06). Planned enrolment is 191 participants (actual). The study started in 2024-11-25 and primary completion is expected in 2027-07-30. No results have been posted on ClinicalTrials.gov.
Shares Acasunlimab, Genmab, Non-small-cell lung cancer.
Shares Genmab, Non-small-cell lung cancer.
Shares Genmab, Non-small-cell lung cancer.
Shares Genmab, Non-small-cell lung cancer.
Shares Genmab, Non-small-cell lung cancer.
Shares Acasunlimab, Non-small-cell lung cancer.
Shares Genmab, Non-small-cell lung cancer.